February 7, 2017
(The Scientist) – Researchers in Japan who have been developing a cell therapy for macular degeneration received support from health authorities this week (February 1) to begin a clinical trial using donor-derived induced pluripotent stem (IPS) cells converted to retinal cells. This will be the first trial in which the team’s physicians administer donor cells, an approach expected to lower costs and preparation time. Previously, this same group of scientists, led by the Riken Center for Developmental Biology’s Masayo Takahashi, tested an iPS cell-based therapy for macular degeneration using the patients’ own cells.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.